ABI-1179

Assembly Biosciences (ASMB) announced promising Phase 1a data for HSV treatments, ABI-5366 and ABI-1179, at recent conferences. These helicase-primase inhibitors demonstrated favorable safety and pharmacokinetics in healthy volunteers, potentially allowing for less frequent dosing: once-weekly for both and potentially once-monthly for ABI-5366. No significant food effect was observed. Phase 1b trials are underway, with interim data expected in fall 2025, a possible inflection point for Assembly Biosciences.